Evaluation of new imaging approaches in Alzheimer's disease
Grant number: 509166 | Funding period: 2008 - 2010
Alzheimer's disease is the most common age-related neurodegenerative disease, and the most common cause of dementia. It is estimated that 212,000 Australians suffer from dementia and this will rise to approximately 730,000 by 2050. Currently there are no definitive diagnostic methods for AD. The research proposed in this application describes the evaluation of a new imaging radiotracer that would be suitable for widespread non-invasive diagnosis of AD.
Related publications (4)
A beta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Kevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Narelle Langdon, Ana M Catafau, Andrew W Stephens, John Seibyl, Ludger M Dinkelborg, Cornelia B Reininger, Barbara Putz, Beate Rohde, Colin L Masters, Christopher C Rowe
In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer
Michelle T Fodero-Tavoletti, Damian Brockschnieder, Victor L Villemagne, Lucas Martin, Andrea R Connor, Andrea Thiele, Mathias Berndt, Catriona A McLean, Sabine Krause, Christopher C Rowe, Colin L Masters, Ludger Dinkelborg, Thomas Dyrks, Roberto Cappai